Financial Performance - Total revenues increased by 23.5% to $58,384,552 for the year ended December 31, 2024, compared to $47,274,162 in 2023[165]. - Pharma industry revenue surged by 212.3%, reaching $12,652,412, driven by the launch of 33 net new pharma programs[165]. - Gross profit increased by 33.4% to $32,197,334, with a gross margin of 55.1% for the year ended December 31, 2024[165][167]. - Net income for the year ended December 31, 2024 was $3,815,907, a decline of 40.9% compared to $6,458,727 in 2023[172]. - The gross dollar volume loaded on cards was $1,783 million for the year ended December 31, 2024, compared to $1,706 million in 2023[173]. - Total revenue conversion rate improved to 3.27% for 2024, up from 2.77% in 2023[174]. - Operating expenses increased by 28.3% to $31,175,826, primarily due to higher selling, general and administrative expenses[165][168]. - Adjusted EBITDA for the year ended December 31, 2024 was $9,621,083, compared to $6,712,966 in 2023[176]. - Net cash provided by operating activities was $22,947,120 in 2024, a decrease of $4,673,504 compared to 2023[179][181]. - Cash used in financing activities was $466,245 for the year ended December 31, 2024, compared to $1,118,284 for 2023, with share repurchases of 136,700 shares at an average price of $3.62 per share in 2024[183]. - Unrestricted cash as of December 31, 2024, was $10,766,982, a decrease of $6,227,723 from the previous year, primarily due to payment timing on claim reimbursement receivables[185]. Business Operations - Paysign reported significant growth in the prepaid card market, driven by improved technology and greater consumer convenience[158]. - The company operates a high-availability payments platform that allows seamless integration with clients' systems, enhancing transaction processing and customer service[151]. - Paysign's prepaid card offerings include corporate rewards, prepaid gift cards, general purpose reloadable debit cards, and healthcare reimbursement payments[152]. - The company manages all aspects of the prepaid card lifecycle, including design, production, distribution, and customer service[159]. - Paysign's architecture is known for its cross-platform compatibility, flexibility, and scalability, providing cost savings and revenue opportunities for clients[151]. - Paysign's marketing efforts are focused on corporate incentive and expense prepaid card products across various market verticals, including healthcare and loyalty rewards[160]. Revenue Recognition - Revenue from plasma and pharma card programs includes cardholder fees, transaction claims processing fees, and interchange fees[193]. - The company recognizes revenue from cardholder fees at the point of transaction fulfillment and management fees on a monthly basis[194]. - Breakage revenue is recognized ratably over the estimated card life, based on historical redemption patterns[195]. Future Outlook - The company plans to invest additional funds in technology improvements, sales and marketing, cybersecurity, fraud prevention, customer service, and regulatory compliance in 2025[163]. - The company anticipates that its available cash and forecasted revenues will sustain operations for the next 24 months[149]. - The company may evaluate raising capital to diversify into new market verticals while believing it can support existing operations with internally generated funds if new capital is not raised[163]. - The company grew to approximately 7.3 million cardholders and approximately 600 card programs as of December 31, 2024[164]. Stock and Compensation - The company repurchased 394,558 shares at an average price of $2.86 per share in 2023[183]. - Stock-based compensation expense is recognized for all restricted stock awards and stock options, with fair value measured at grant date[200]. Compliance and Risk - Operating lease expenses are recorded as rent expense and included within selling, general, and administrative expenses[198]. - The company is not required to provide market risk disclosures as a smaller reporting company[201].

Paysign, Inc. (NASDAQ:PAYS) Q4 2024 Earnings Conference Call March 25, 2025 5:00 PM ET Company Participants Mark Newcomer - President and CEO Jeff Baker - CFO Matt Turner - President, Patient Affordability Matt Lanford - CPO Conference Call Participants Jacob Stephan - Lake Street Capital Markets Gary Prestopino - Barrington Research Peter Heckmann - D.A. Davidson Operator Good afternoon. My name is Kevin and I'll be your conference operator today. At this time, I'd like to welcome everyone to the Paysign, ...

Exhibit 99.1 Earnings Release Paysign, Inc. Reports Fourth Quarter and Full-Year 2024 Financial Results For the Full-Year 1 · Full-year 2024 total revenues of $58.38 million, up 23.5% from full-year 2023 · Full-year 2024 net income of $3.82 million, or diluted earnings per share of $0.07, versus net income of $6.46 million, or diluted earnings per share of $0.12 for full-year 2023 · Full-year 2024 Adjusted EBITDA of $9.62 million, up 43.3% from $6.71 million a year ago, while diluted Adjusted EBITDA per sha ...

Group 1 - Paysign, Inc. operates in the healthcare-focused Fintech sector and has made significant inroads into the estimated $500 million Patient Affordability market [1] - The company has achieved an impressive average revenue growth of 230% over the past four quarters specifically in its Pharma segment [1] - Despite being a small company, Paysign, Inc. has demonstrated strong performance metrics that may indicate potential investment opportunities [1]

Core Insights - Paysign (NASDAQ: PAYS) is identified as a U.S. microcap payment processing business that has been closely monitored for over a decade [1] Company Overview - The company has experienced significant stock movement, with a notable increase of approximately 12 times since May 2018 [1]

Revenue Growth - Total revenues for the three months ended September 30, 2024, increased by $2,856,106, or 23.0%, compared to the same period in 2023, reaching $15,256,431[90]. - Total revenues for the nine months ended September 30, 2024 were $42,778,104, a 27.4% increase from $33,584,666 in the prior year[100]. - Plasma industry revenue rose by $377,822, or 3.4%, to $11,439,534, driven by the addition of 16 net new plasma centers and increased donations[91]. - Plasma industry revenue for the nine months ended September 30, 2024 increased by $2,644,590, while pharma industry revenue surged by $5,993,365[100]. - Pharma industry revenue surged by $2,248,618, or 219.1%, to $3,274,888, attributed to the launch of 32 new patient affordability programs[91]. Profitability - Gross profit for the three months ended September 30, 2024, increased by $2,141,196, or 33.8%, resulting in a gross margin of 55.5%[90][93]. - Gross profit for the nine months ended September 30, 2024 increased by $6,002,801, resulting in a gross margin of 53.8%[103]. - Net income for the period was $1,436,837, reflecting a 30.5% increase compared to the prior year, with a net margin of 9.42%[88]. - Net income for the three months ended September 30, 2024 was $1,436,837, an increase of $336,233 compared to the same period in 2023[98]. - Net income for the nine months ended September 30, 2024 was $2,443,035, an improvement of $1,606,717 compared to the prior year[108]. - Adjusted EBITDA for the nine months ended September 30, 2024, was $6,756,410, up 60.5% from $4,207,363 in 2023[113]. Operating Expenses - Operating expenses totaled $7,783,465, an increase of $2,041,779, or 35.6%, with selling, general and administrative expenses rising by 32.4%[88]. - Selling, general and administrative expenses for the three months ended September 30, 2024 increased by $1,521,335, primarily due to a $1,821,000 rise in compensation and benefits[94]. - Selling, general and administrative expenses for the nine months ended September 30, 2024 rose by $3,202,922, mainly due to a $4,012,000 increase in compensation and benefits[104]. - Depreciation and amortization expense for the three months ended September 30, 2024 increased by $520,444, driven by new software development costs and equipment purchases[95]. Cash Flow and Investments - Operating activities provided $8,633,922 of cash, an increase of 106.5% compared to $4,180,064 in the prior year[116]. - Cash used in investing activities was $7,087,867 for the nine months ended September 30, 2024, compared to $4,999,986 in 2023, reflecting increased investment in technology[117]. - Unrestricted cash as of September 30, 2024, was $10,293,207, an increase of 3.6% from $9,936,627 in the prior year[120]. - Financing activities used $331,695 in cash, primarily for the repurchase of 100,000 shares at an average price of $3.60 per share[118]. - The company financed operations through internally generated funds during the nine months ended September 30, 2024[115]. Future Outlook - The company plans to continue investing in technology improvements, sales and marketing, and regulatory compliance in 2024[89]. - Future product expansions are expected to include travel cards and expense reimbursement cards[78]. - The company continues to monitor bank relationships amid elevated interest rates and refinancing risks in commercial real estate[120]. Market Trends - The prepaid card market in the U.S. has seen significant growth, driven by improved technology and increased consumer adoption[84]. - The company manages all aspects of the prepaid card lifecycle, enhancing customer service with a fully staffed, in-house department[85]. Operational Performance - Income from operations for the three months ended September 30, 2024 was $689,849, an improvement of $99,417 compared to the prior year[96]. - Gross dollar volume loaded on cards was $456 million for the three months ended September 30, 2024, compared to $448 million in the same period of 2023[110]. - The increase in cash flows from operating activities was impacted by net income and non-cash adjustments for depreciation and amortization[116]. - Significant contractual cash requirements include ongoing payments for lease liabilities[119].

Paysign, Inc. (NASDAQ:PAYS) Q3 2024 Earnings Conference Call November 5, 2024 5:00 PM ET Company Participants Mark Newcomer - President and CEO Jeff Baker - CFO Matt Turner - President, Patient Affordability Conference Call Participants Pete Heckmann - D.A. Davidson Gary Prestopino - Barrington Research Jon Hickman - Ladenburg Thalmann Operator Good afternoon. My name is Kevin, and I'll be your conference operator today. At this time, I'd like to welcome everyone to the Paysign, Inc.'s Third Quarter 2024 Ea ...

Exhibit 99.1 1 Paysign, Inc. Reports Third Quarter 2024 Financial Results · Third quarter 2024 total revenues of $15.26 million, up 23.0% from third quarter 2023 · Third quarter 2024 net income of $1.44 million, or diluted earnings per share of $0.03, versus net income of $1.10 million, or diluted earnings per share of $0.02 for third quarter 2023 · Third quarter 2024 Adjusted EBITDA of $2.83 million, up 20.6% from $2.35 million for third quarter 2023, while diluted Adjusted EBITDA per share was $0.05 versu ...

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks. Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use tried-and-true metrics and fundamental analysis ...

The Business Services group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Paysign, Inc. (PAYS) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Business Services sector should help us answer this question. Paysign, Inc. is one of 317 individual stocks in the Bus ...